Solid Biosciences shares drop 70% on disappointing Duchenne data
February 07, 2019 at 10:45 AM EST
Cambridge biotech Solid Biosciences' stock dropped more than 70 percent Thursday after its Duchenne muscular dystrophy drug failed to come close to the effectiveness of its competitor in early tests.
